Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects
Open Access
- 22 August 2005
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 36 (9), 771-779
- https://doi.org/10.1038/sj.bmt.1705138
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantationBone Marrow Transplantation, 2001
- Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myelomaBone Marrow Transplantation, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Multiple MyelomaNew England Journal of Medicine, 1997
- Cytokine-binding proteins: stimulating antagonistsImmunology Today, 1995
- Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6Clinical and Experimental Immunology, 1994
- Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodiesMolecular Immunology, 1991
- In vivo interleukin 6 gene expression in the tumoral environment in multiple myelomaEuropean Journal of Immunology, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958